B-intervention	0	10	Ribociclib
I-intervention	11	15	plus
I-intervention	16	25	letrozole
O	26	32	versus
B-control	33	45	chemotherapy
O	46	49	for
O	50	64	postmenopausal
O	65	70	women
O	71	75	with
O	76	83	hormone
O	84	92	receptor
O	92	93	-
O	93	101	positive
O	101	102	,
O	103	107	HER2
O	107	108	-
O	108	116	negative
O	116	117	,
O	118	125	luminal
O	126	127	B
O	128	134	breast
O	135	141	cancer
O	142	143	(
O	143	152	CORALLEEN
O	152	153	)
O	153	154	:
O	155	157	an
O	158	162	open
O	162	163	-
O	163	168	label
O	168	169	,
O	170	181	multicentre
O	181	182	,
O	183	193	randomised
O	193	194	,
O	195	200	phase
O	201	202	2
O	203	208	trial
O	208	209	.

O	210	212	In
O	213	220	hormone
O	221	229	receptor
O	229	230	-
O	230	238	positive
O	238	239	,
O	240	244	HER2
O	244	245	-
O	245	253	negative
O	254	259	early
O	260	265	stage
O	266	272	breast
O	273	279	cancer
O	279	280	,
O	281	287	cyclin
O	287	288	-
O	288	297	dependent
O	298	305	kinases
O	306	307	4
O	308	311	and
O	312	313	6
O	314	315	(
O	315	319	CDK4
O	319	320	/
O	320	321	6
O	321	322	)
O	323	333	inhibition
O	334	336	in
O	337	348	combination
O	349	353	with
O	354	363	endocrine
O	364	371	therapy
O	372	377	could
O	378	387	represent
O	388	390	an
O	391	402	alternative
O	403	405	to
O	406	416	multiagent
O	417	429	chemotherapy
O	429	430	.

O	431	433	We
O	434	439	aimed
O	440	442	to
O	443	451	evaluate
O	452	455	the
O	456	466	biological
O	467	470	and
O	471	479	clinical
O	480	488	activity
O	489	491	of
O	492	503	neoadjuvant
O	504	514	ribociclib
O	515	519	plus
O	520	529	letrozole
O	530	532	in
O	533	536	the
O	537	544	luminal
O	545	546	B
O	547	554	subtype
O	555	557	of
O	558	563	early
O	564	569	stage
O	570	576	breast
O	577	583	cancer
O	583	584	.

O	585	594	CORALLEEN
O	595	597	is
O	598	599	a
O	600	608	parallel
O	608	609	-
O	609	612	arm
O	612	613	,
O	614	625	multicentre
O	625	626	,
O	627	637	randomised
O	637	638	,
O	639	643	open
O	643	644	-
O	644	649	label
O	649	650	,
O	651	656	phase
O	657	658	2
O	659	664	trial
O	665	674	completed
O	675	681	across
O	682	684	21
O	685	694	hospitals
O	695	697	in
B-location	698	703	Spain
O	703	704	.

O	705	707	We
O	708	717	recruited
O	718	732	postmenopausal
O	733	738	women
O	739	740	(
B-age	740	741	≥
I-age	741	743	18
I-age	744	749	years
O	749	750	)
B-eligibility	751	755	with
I-eligibility	756	761	stage
I-eligibility	762	763	I
I-eligibility	763	764	-
I-eligibility	764	768	IIIA
I-eligibility	769	776	hormone
I-eligibility	777	785	receptor
I-eligibility	785	786	-
I-eligibility	786	794	positive
O	794	795	,
O	796	803	Eastern
O	804	815	Cooperative
O	816	824	Oncology
O	825	830	Group
O	831	842	Performance
O	843	849	Status
O	850	851	0
O	851	852	-
O	852	853	1
O	853	854	,
O	855	859	HER2
O	859	860	-
O	860	868	negative
O	869	875	breast
O	876	882	cancer
O	883	886	and
O	887	894	luminal
O	895	896	B
O	897	899	by
O	900	905	PAM50
O	906	910	with
O	911	925	histologically
O	926	935	confirmed
O	935	936	,
O	937	945	operable
O	946	953	primary
O	954	960	tumour
O	961	965	size
O	966	968	of
O	969	971	at
O	972	977	least
O	978	979	2
O	980	982	cm
O	983	985	in
O	986	994	diameter
O	995	997	as
O	998	1006	measured
O	1007	1009	by
O	1010	1013	MRI
O	1013	1014	.

O	1015	1023	Patients
O	1024	1028	were
O	1029	1037	randomly
O	1038	1046	assigned
O	1047	1048	(
O	1048	1049	1
O	1049	1050	:
O	1050	1051	1
O	1051	1052	)
O	1053	1058	using
O	1059	1060	a
O	1061	1064	web
O	1064	1065	-
O	1065	1070	based
O	1071	1077	system
O	1078	1081	and
O	1082	1090	permuted
O	1091	1097	blocks
O	1098	1100	of
O	1101	1103	25
O	1104	1106	to
O	1107	1114	receive
O	1115	1121	either
O	1122	1125	six
O	1126	1128	28
O	1128	1129	-
O	1129	1133	days
O	1134	1140	cycles
O	1141	1143	of
O	1144	1154	ribociclib
O	1155	1156	(
O	1156	1160	oral
O	1161	1164	600
O	1165	1167	mg
O	1168	1172	once
O	1173	1178	daily
O	1179	1182	for
O	1183	1184	3
O	1185	1190	weeks
O	1191	1193	on
O	1193	1194	,
O	1195	1196	1
O	1197	1201	week
O	1202	1205	off
O	1205	1206	)
O	1207	1211	plus
O	1212	1217	daily
O	1218	1227	letrozole
O	1228	1229	(
O	1229	1233	oral
O	1234	1235	2
O	1235	1236	·
O	1236	1237	5
O	1238	1240	mg
O	1240	1241	/
O	1241	1244	day
O	1244	1245	)
O	1246	1248	or
O	1249	1253	four
O	1254	1260	cycles
O	1261	1263	of
O	1264	1275	doxorubicin
O	1276	1277	(
O	1277	1288	intravenous
O	1289	1291	60
O	1292	1294	mg
O	1294	1295	/
O	1295	1297	m2
O	1297	1298	)
O	1299	1302	and
O	1303	1319	cyclophosphamide
O	1320	1321	(
O	1321	1332	intravenous
O	1333	1336	600
O	1337	1339	mg
O	1339	1340	/
O	1340	1342	m2
O	1342	1343	)
O	1344	1349	every
O	1350	1352	21
O	1353	1357	days
O	1358	1366	followed
O	1367	1369	by
O	1370	1376	weekly
O	1377	1387	paclitaxel
O	1388	1389	(
O	1389	1400	intravenous
O	1401	1403	80
O	1404	1406	mg
O	1406	1407	/
O	1407	1409	m2
O	1409	1410	)
O	1411	1414	for
O	1415	1417	12
O	1418	1423	weeks
O	1423	1424	.

O	1425	1428	The
O	1429	1434	total
O	1435	1443	duration
O	1444	1446	of
O	1447	1450	the
O	1451	1462	neoadjuvant
O	1463	1470	therapy
O	1471	1474	was
O	1475	1477	24
O	1478	1483	weeks
O	1483	1484	.

O	1485	1498	Randomisation
O	1499	1502	was
O	1503	1513	stratified
O	1514	1516	by
O	1517	1523	tumour
O	1524	1528	size
O	1529	1532	and
O	1533	1538	nodal
O	1539	1550	involvement
O	1550	1551	.

O	1552	1559	Samples
O	1560	1564	were
O	1565	1578	prospectively
O	1579	1588	collected
O	1589	1591	at
O	1592	1600	baseline
O	1601	1602	(
O	1602	1605	day
O	1606	1607	0
O	1607	1608	)
O	1608	1609	,
O	1610	1613	day
O	1614	1616	15
O	1616	1617	,
O	1618	1621	and
O	1622	1629	surgery
O	1629	1630	.

O	1631	1634	The
O	1635	1642	primary
O	1643	1651	endpoint
O	1652	1655	was
O	1656	1658	to
O	1659	1667	evaluate
O	1668	1671	the
B-outcome-Measure	1672	1682	proportion
I-outcome-Measure	1683	1685	of
I-outcome-Measure	1686	1694	patients
I-outcome-Measure	1695	1699	with
I-outcome-Measure	1700	1705	PAM50
I-outcome-Measure	1706	1709	low
I-outcome-Measure	1709	1710	-
I-outcome-Measure	1710	1714	risk
I-outcome-Measure	1714	1715	-
I-outcome-Measure	1715	1717	of
I-outcome-Measure	1717	1718	-
I-outcome-Measure	1718	1725	relapse
I-outcome-Measure	1726	1727	(
I-outcome-Measure	1727	1730	ROR
I-outcome-Measure	1730	1731	)
I-outcome-Measure	1732	1739	disease
I-outcome-Measure	1740	1742	at
I-outcome-Measure	1743	1750	surgery
O	1751	1753	in
O	1754	1757	the
O	1758	1766	modified
O	1767	1776	intention
O	1776	1777	-
O	1777	1779	to
O	1779	1780	-
O	1780	1785	treat
O	1786	1796	population
O	1797	1806	including
O	1807	1810	all
O	1811	1819	randomly
O	1820	1828	assigned
O	1829	1837	patients
O	1838	1841	who
O	1842	1850	received
O	1851	1856	study
O	1857	1861	drug
O	1862	1865	and
O	1866	1869	had
O	1870	1871	a
O	1872	1880	baseline
O	1881	1884	and
O	1885	1887	at
O	1888	1893	least
O	1894	1897	one
O	1898	1902	post
O	1902	1903	-
O	1903	1911	baseline
O	1912	1923	measurement
O	1924	1926	of
O	1927	1930	ROR
O	1931	1936	score
O	1936	1937	.

O	1938	1941	The
O	1942	1947	PAM50
O	1948	1951	ROR
O	1952	1956	risk
O	1957	1962	class
O	1963	1973	integrated
O	1974	1978	gene
O	1979	1989	expression
O	1990	1994	data
O	1994	1995	,
O	1996	2002	tumour
O	2003	2007	size
O	2007	2008	,
O	2009	2012	and
O	2013	2018	nodal
O	2019	2025	status
O	2026	2028	to
O	2029	2035	define
O	2036	2045	prognosis
O	2045	2046	.

O	2047	2051	This
O	2052	2057	trial
O	2058	2061	was
O	2062	2072	registered
O	2073	2075	at
O	2076	2090	ClinicalTrials
O	2090	2091	.
O	2092	2095	gov
O	2095	2096	,
O	2097	2108	NCT03248427
O	2108	2109	.

O	2110	2117	Between
O	2118	2122	July
O	2123	2125	27
O	2125	2126	,
O	2127	2131	2017
O	2132	2134	to
O	2135	2138	Dec
O	2139	2140	7
O	2140	2141	,
O	2142	2146	2018
O	2146	2147	,
B-total-participants	2148	2151	106
O	2152	2160	patients
O	2161	2165	were
O	2166	2174	enrolled
O	2174	2175	.

O	2176	2178	At
O	2179	2187	baseline
O	2187	2188	,
O	2189	2191	of
O	2192	2195	the
O	2196	2199	106
O	2200	2208	patients
O	2208	2209	,
O	2210	2212	92
O	2213	2214	(
O	2214	2216	87
O	2216	2217	%
O	2217	2218	)
O	2219	2227	patients
O	2228	2231	had
B-outcome	2232	2236	high
I-outcome	2237	2240	ROR
I-outcome	2241	2248	disease
O	2249	2250	(
B-iv-bin-abs	2250	2252	44
O	2253	2254	[
B-iv-bin-percent	2254	2256	85
I-iv-bin-percent	2256	2257	%
O	2257	2258	]
O	2259	2261	of
B-intervention-participants	2262	2264	52
O	2265	2267	in
O	2268	2271	the
O	2272	2282	ribociclib
O	2283	2286	and
O	2287	2296	letrozole
O	2297	2302	group
O	2303	2306	and
B-cv-bin-abs	2307	2309	48
O	2310	2311	[
B-cv-bin-percent	2311	2313	89
I-cv-bin-percent	2313	2314	%
O	2314	2315	]
O	2316	2318	of
B-control-participants	2319	2321	54
O	2322	2324	in
O	2325	2328	the
O	2329	2341	chemotherapy
O	2342	2347	group
O	2347	2348	)
O	2349	2352	and
O	2353	2355	14
O	2356	2357	(
O	2357	2359	13
O	2359	2360	%
O	2360	2361	)
O	2362	2370	patients
O	2371	2374	had
B-outcome	2375	2387	intermediate
I-outcome	2387	2388	-
I-outcome	2388	2391	ROR
I-outcome	2392	2399	disease
O	2400	2401	(
B-iv-bin-abs	2401	2406	eight
O	2407	2408	[
B-iv-bin-percent	2408	2410	15
I-iv-bin-percent	2410	2411	%
O	2411	2412	]
O	2413	2416	and
B-cv-bin-abs	2417	2420	six
O	2421	2422	[
B-cv-bin-percent	2422	2424	11
I-cv-bin-percent	2424	2425	%
O	2425	2426	]
O	2426	2427	)
O	2427	2428	.

O	2429	2435	Median
O	2436	2442	follow
O	2442	2443	-
O	2443	2445	up
O	2446	2449	was
O	2450	2453	200
O	2453	2454	·
O	2454	2455	0
O	2456	2460	days
O	2461	2462	(
O	2462	2465	IQR
O	2466	2469	191
O	2469	2470	·
O	2470	2471	2
O	2471	2472	-
O	2472	2475	206
O	2475	2476	·
O	2476	2477	0
O	2477	2478	)
O	2478	2479	.

O	2480	2482	At
O	2483	2490	surgery
O	2490	2491	,
B-iv-bin-abs	2492	2494	23
O	2495	2496	(
O	2496	2498	46
O	2498	2499	·
O	2499	2500	9
O	2500	2501	%
O	2501	2502	;
O	2503	2505	95
O	2505	2506	%
O	2507	2509	CI
O	2510	2512	32
O	2512	2513	·
O	2513	2514	5
O	2514	2515	-
O	2515	2517	61
O	2517	2518	·
O	2518	2519	7
O	2519	2520	)
O	2521	2523	of
B-intervention-participants	2524	2526	49
O	2527	2535	patients
O	2536	2538	in
O	2539	2542	the
O	2543	2553	ribociclib
O	2554	2558	plus
O	2559	2568	letrozole
O	2569	2574	group
O	2575	2578	and
B-cv-bin-abs	2579	2581	24
O	2582	2583	(
O	2583	2585	46
O	2585	2586	·
O	2586	2587	1
O	2587	2588	%
O	2588	2589	;
O	2590	2592	32
O	2592	2593	·
O	2593	2594	9
O	2594	2595	-
O	2595	2597	61
O	2597	2598	·
O	2598	2599	5
O	2599	2600	)
O	2601	2603	of
B-control-participants	2604	2606	52
O	2607	2615	patients
O	2616	2618	in
O	2619	2622	the
O	2623	2635	chemotherapy
O	2636	2641	group
O	2642	2646	were
B-outcome	2647	2650	low
I-outcome	2650	2651	-
I-outcome	2651	2654	ROR
O	2654	2655	.

O	2656	2659	The
O	2660	2664	most
O	2665	2671	common
B-outcome	2672	2677	grade
I-outcome	2678	2679	3
I-outcome	2679	2680	-
I-outcome	2680	2681	4
I-outcome	2682	2689	adverse
I-outcome	2690	2696	events
O	2697	2699	in
O	2700	2703	the
O	2704	2714	ribociclib
O	2715	2719	plus
O	2720	2729	letrozole
O	2730	2735	group
O	2736	2740	were
B-outcome	2741	2752	neutropenia
O	2753	2754	(
B-iv-bin-abs	2754	2756	22
O	2757	2758	[
B-iv-bin-percent	2758	2760	43
I-iv-bin-percent	2760	2761	%
O	2761	2762	]
O	2763	2765	of
B-intervention-participants	2766	2768	51
O	2769	2777	patients
O	2777	2778	)
O	2779	2782	and
B-outcome	2783	2791	elevated
I-outcome	2792	2799	alanine
I-outcome	2800	2816	aminotransferase
I-outcome	2817	2831	concentrations
O	2832	2833	(
B-iv-bin-abs	2833	2836	ten
O	2837	2838	[
B-iv-bin-percent	2838	2840	20
I-iv-bin-percent	2840	2841	%
O	2841	2842	]
O	2842	2843	)
O	2843	2844	.

O	2845	2848	The
O	2849	2853	most
O	2854	2860	common
B-outcome	2861	2866	grade
I-outcome	2867	2868	3
I-outcome	2868	2869	-
I-outcome	2869	2870	4
I-outcome	2871	2878	adverse
I-outcome	2879	2885	events
O	2886	2888	in
O	2889	2892	the
O	2893	2905	chemotherapy
O	2906	2911	group
O	2912	2916	were
B-outcome	2917	2928	neutropenia
O	2929	2930	(
B-cv-bin-abs	2930	2932	31
O	2933	2934	[
B-cv-bin-percent	2934	2936	60
I-cv-bin-percent	2936	2937	%
O	2937	2938	]
O	2939	2941	of
B-control-participants	2942	2944	52
O	2945	2953	patients
O	2953	2954	)
O	2955	2958	and
B-outcome	2959	2966	febrile
I-outcome	2967	2978	neutropenia
O	2979	2980	(
B-cv-bin-abs	2980	2985	seven
O	2986	2987	[
B-cv-bin-percent	2987	2989	13
I-cv-bin-percent	2989	2990	%
O	2990	2991	]
O	2991	2992	)
O	2992	2993	.

O	2994	2996	No
B-outcome	2997	3003	deaths
O	3004	3008	were
O	3009	3017	observed
O	3018	3024	during
O	3025	3028	the
O	3029	3034	study
O	3035	3037	in
O	3038	3044	either
O	3045	3050	group
O	3050	3051	.

O	3052	3055	Our
O	3056	3063	results
O	3064	3071	suggest
O	3072	3076	that
O	3077	3081	some
O	3082	3090	patients
O	3091	3095	with
O	3096	3100	high
O	3100	3101	-
O	3101	3105	risk
O	3105	3106	,
O	3107	3112	early
O	3113	3118	stage
O	3118	3119	,
O	3120	3127	hormone
O	3128	3136	receptor
O	3136	3137	-
O	3137	3145	positive
O	3145	3146	,
O	3147	3151	HER2
O	3151	3152	-
O	3152	3160	negative
O	3161	3167	breast
O	3168	3174	cancer
O	3175	3180	could
O	3181	3188	achieve
O	3189	3198	molecular
O	3199	3210	downstaging
O	3211	3213	of
O	3214	3219	their
O	3220	3227	disease
O	3228	3232	with
O	3233	3237	CDK4
O	3237	3238	/
O	3238	3239	6
O	3240	3249	inhibitor
O	3250	3253	and
O	3254	3263	endocrine
O	3264	3271	therapy
O	3271	3272	.

O	3273	3281	Novartis
O	3281	3282	,
O	3283	3293	Nanostring
O	3293	3294	,
O	3295	3301	Breast
O	3302	3308	Cancer
O	3309	3317	Research
O	3318	3328	Foundation
O	3328	3329	-
O	3329	3333	AACR
O	3334	3340	Career
O	3341	3352	Development
O	3353	3358	Award
O	3358	3359	.
